Mode
Text Size
Log in / Sign up
N/A N=12 Randomized Double-blind Treatment

Improving Hallucinations by Targeting the rSTS With tES

Hallucinations, Auditory · Psychosis

Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Positive and Negative Syndrome Scale (PANSS) — 60.5; 60; 56; 63 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transcranial Electrical Stimulation (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Beth Israel Deaconess Medical Center
Primary completion
Jun 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Positive and Negative Syndrome Scale (PANSS)
60.5; 60; 58.5; 70.5
PRIMARY
Positive and Negative Syndrome Scale (PANSS)
60.5; 60; 58.5; 70.5
PRIMARY
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
1.85; 1.9; 1.4; 2.35
PRIMARY
University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ)
1.85; 1.9; 1.4; 2.35
PRIMARY
7-item Auditory Hallucinations Rating Scale (AHRS)
0; 8; 0; 6
PRIMARY
7-item Auditory Hallucinations Rating Scale (AHRS)
0; 8; 0; 6
SECONDARY
Auditory Steady State Evoked Potential
0.369044853; 0.434681797; 0.307252913; 0.221649958
SECONDARY
Auditory Steady State Evoked Potential
0.369044853; 0.434681797; 0.307252913; 0.221649958
SECONDARY
Steady State Visual Evoked Potential
-0.62131125; -0.046333327; 0.276320034; -0.342125912
SECONDARY
Steady State Visual Evoked Potential
-0.62131125; -0.046333327; 0.276320034; -0.342125912
SECONDARY
Cross Modal Steady State Evoked Potential
-0.129873057; -0.225582699; -0.372064254; -0.370288832
SECONDARY
Cross Modal Steady State Evoked Potential
-0.129873057; -0.225582699; -0.372064254; -0.370288832
SECONDARY
Resting State EEG
-6.067479336; -9.836502863; -5.891239776; -8.925939219; -7.920960953; -11.66579035
SECONDARY
Resting State EEG
-6.067479336; -9.836502863; -5.891239776; -8.925939219; -7.920960953; -11.66579035
SECONDARY
Biological Motion
87.5; 85; 95; 85
SECONDARY
Biological Motion
87.5; 85; 95; 85
SECONDARY
Neurological Evaluation Scale; Sensory Integration
SECONDARY
Neurological Evaluation Scale; Sensory Integration
SECONDARY
Global Assessment of Function (GAF)
60.5; 57.5; 61.5; 54
SECONDARY
Global Assessment of Function (GAF)
60.5; 57.5; 61.5; 54
SECONDARY
Montgomery-Asberg Depression Rating Scale (MADRS)
7; 7.5; 5.5; 13
SECONDARY
Montgomery-Asberg Depression Rating Scale (MADRS)
7; 7.5; 5.5; 13
SECONDARY
Young Mania Rating Scale (YMRS)
2.25; 7; 2; 8.75
SECONDARY
Young Mania Rating Scale (YMRS)
2.25; 7; 2; 8.75
SECONDARY
Brief Assessment of Cognition (BACS)
0.58; -0.8; -0.07; -1.425
SECONDARY
Brief Assessment of Cognition (BACS)
0.58; -0.8; -0.07; -1.425
SECONDARY
Symptom Checklist-90
56.5; 81.5; 42; 95.5
SECONDARY
Symptom Checklist-90
56.5; 81.5; 42; 95.5

Summary

Hallucinations are a core diagnostic feature of psychotic disorders. They involve different sensory modalities, including auditory, visual, olfactory, tactile, and gustatory hallucinations, among others. Hallucinations occur in multiple different neurological and psychiatric illnesses and can be refractory to existing treatments. Auditory hallucinations and visual hallucinations are found across diagnostic categories of psychotic disorders (schizophrenia, schizoaffective, bipolar disorder). Despite visual hallucinations being approximately half as frequent as auditory hallucinations, they almost always co-occur with auditory hallucinations, and are linked to a more severe psychopathological profile. Auditory and visual hallucinations at baseline also predict higher disability, risk of relapse and duration of psychosis after 1 and 2 years, especially when they occur in combination. Using a newly validated technique termed lesion network mapping, researchers demonstrated that focal brain lesions connected to the right superior temporal sulcus (rSTS) plays a causal role in the development of hallucinations. The rSTS receives convergent somatosensory, auditory, and visual inputs, and is regarded as a site for multimodal sensory integration. Here the investigators aim to answer the question whether noninvasive brain stimulation when optimally targeted to the rSTS can improve brain activity, sensory integration, and hallucinations.

Eligibility Criteria

Inclusion Criteria

  • Aged 18-50 years of age
  • Proficient in English
  • Able to give informed consent
  • Actively experiencing hallucinations (tactile, auditory, visual, etc.)
  • Has not recently participated in tES/TMS treatments

Exclusion Criteria

  • Substance abuse or dependence (w/in past 6 months)
  • Those who are pregnant/breastfeeding
  • History of head injury with > 15 minutes of loss of consciousness/mal sequelae
  • DSM-V intellectual disability
  • Having a non-removable ferromagnetic metal within the body (particularly in the head)
  • History of seizures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05165654). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search